GATA1 and Dravet syndrome: Pending studies will determine whether periodic mutation screening can improve outcomes for these infants with “silent” TAM and thus the clinical utility of screening for GATA1 mutations in all patients with DS (Roberts et al. 2013; Bhatnagar et al. 2016).